A Phase 3 interventional study of Risk based screening in Breast Cancer, sponsored by Karolinska Institutet. Not yet recruiting. Open to female participants aged 40 Years to 74 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-02-28.
Sponsored by Karolinska Institutet · Phase 3, Interventional, and Screening
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Breast Neoplasms by Karolinska Institutet — 4 open to participants now, 6 under way, 2 of them phase 3. Breast Neoplasms · Karolinska Institutet.
Among the 19 studies in Breast Neoplasms by Karolinska Institutet, this one has the largest planned enrollment of the 18 interventional ones that give a count, is the only one that started in 2024, is one of 3 in phase 3, and was the 16th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →4 of the 19 studies in Breast Neoplasms by Karolinska Institutet are open now, in 5 countries. Recruiting first, the newest first:
Karolinska Institutet · Sites in Finland, Korea, Republic of, Sweden
Ages 18+
Karolinska Institutet · Sites in Sweden
Ages 18+ · Women only
Karolinska Institutet · Sites in Australia, Finland, Sweden and 1 more country
Ages 18–100
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 40 Years to 74 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 3
First in 1977; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 70,000 is above the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 175 across the 18 interventional studies, 35,002 across the 1 observational. Of the 10 that completed or were terminated, 1 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
Karolinska Institutet is the lead sponsor of 1,150 studies on the registry; 276 are open to participants now.
1 of the studies in Breast Neoplasms by Karolinska Institutet that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06471452Karolinska InstitutetTo Live Better After Breast Cancer Treatment | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 19 studies in Breast Neoplasms by Karolinska Institutet, from their registry updates:
This tab as a report to print or save as PDF → With an account.
SMART is a Phase III, randomised, non-blinded screening trial. Women who consent to participate in SMART are randomised to either individualised screening or screening according to the Swedish National Breast Cancer Screening Program. Women randomised to individualised screening get their 2-year risk of breast cancer assessed and women with the highest short-term risk are offered contrast enhanced mammography and a mammogram at 12 months.
Aims: The overarching aim of SMART is to compare the effectiveness of current screening practice with individualised breast cancer screening. In SMART women who recently had a normal mammogram will be randomised to either age based or individualised screening. Women randomised to individualised screening will have their 2-year breast cancer risk assessed upfront. This is done via an artificial intelligence (AI) derived analyses of the mammograms. Women scored with the highest 2-year risk will be offered a contrast enhanced mammography and an additional mammography at 12 months. The possible benefits of individualised screening will be contrasted to the possible harms defined as unnecessary recalls, biopsies and induced anxiety and worry.
Primary Objectives: The primary benefit endpoint is a comparison of the proportion of interval cancers in the intervention and comparison group. The primary safety endpoint is the number of screen-initiated recalls and biopsies which do not lead to a cancer diagnosis.
Secondary Objectives: The secondary benefit endpoint is a comparison of the tumor characteristics of diagnosed cancers in the intervention and comparison group. The investigators will also compare differences in cancer worry, anxiety and / or depression between the intervention and control groups.
Explorative Objectives: To describe the possible side effects related to contrast enhanced mammography and compare them to those experienced after an ordinary mammogram. Cost-effectiveness as measured using incremental cost-effectiveness ratio and willingness-to-pay amount.
Primary Endpoint: For women at high 2-year risk in the intervention arm interval cancers are defined as cancers diagnosed in the interval between contrast enhanced mammography (CEM) and 12-month mammogram plus in the interval between 12- and 24-month interval. For the remaining women in the trial interval cancers are defined as cancers diagnosed between baseline mammography and 24-month mammography.
Information on date of diagnosis and mode of detection (screen detected or interval cancer) is derived from the National Quality Registry for Breast Cancer. To certify the correct diagnosis, the investigators will also use the electronic medical records, Take Care, at Södersjukhuset. Information on number of recalled women and number of biopsies will gathered from the Radiation Information System at the hospital.
Secondary Endpoint: Information on date of diagnosis and tumour characteristics (eg. stage, receptor status) is derived from the National Quality Registry for Breast Cancer. The investigators will compare how the screening modalities are perceived using answers from the self-reported Cancer Worry Scale and State Trait Anxiety Inventory.
Explorative Endpoint: The possible side effects related to contrast enhanced mammography and ordinary mammography will be identified using the self-reported Test Morbidity Index.
Study design: SMART is a Phase III, randomised, non-blinded screening trial. Women who consent to participate in SMART are randomised to either individualised screening or screening according to the Swedish National Breast Cancer Screening Program. Women randomised to individualised screening get their 2-year risk of breast cancer assessed and women with the highest short-term risk are offered contrast enhanced mammography and a mammogram at 12 months.
Study population: Women invited for screening according to the Swedish National Breast Cancer Screening Program at Södersjukhuset, that is, age range 40 - 74 years of age, will be invited to participate in SMART.
Number of included participants: Participants will be matched 1:1 with 35,000 women in each arm.
Intervention: Women randomised to the individualised screening arm and judged to be at high risk will be invited to a contrast enhanced mammography and a mammography after 12 months. The intervention is thus a different selection of women compared to what is done today.
Study Duration: There will be two database locks in SMART. The primary lock is done after approximately four years and two months. Women participating in SMART are part of the initial recruitment phase for a total of two years. They perform mammograms at baseline and 24 months. Adding the 2 year follow up for the lastly recruited participant makes a full trial period 4 years in total, with a further two months allowed to capture women whose scan is delayed. After two months the investigators will consider that screening visit to have been missed. The number of high-risk women will be slightly more than 6,000 in each arm (see 10.1 Population / Power). In addition, a second data lock will be performed after 8 years and two months from the start of the trial, that is, after a fourth round of screens (baseline plus 3 routine follow up mammograms). The same objectives and endpoints will be addressed as after the first data base lock with the exception of questionnaire data. Questionnaire data will only be collected between baseline and the next screen in 24 months. SMART will start in 2024, recruit women for 2 years and follow all women for 6 years. The study will thus end in 2032.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
For women that will be offered contrast enhanced mammography the clinically accepted and applied exclusion criteria will be used. Women who cannot perform a contrast mammography will be offered an automated ultrasound.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Women randomised to the experimental arm / individualised screening will have their 2-year breast cancer risk assessed upfront. This is done via an AI (artificial intelligence) derived analyses of the mammograms. Women scored with the highest 2-year risk will be offered a contrast enhanced mammography and an additional mammography at 12 months.
Procedure: Risk based screening
The 35,000 women randomised to the no intervention arm will continue in the Swedish National Breast Cancer Screening Program. This means that they are invited for the next mammography screening after 24 months.
Procedure: Risk based screening
Women randomised to the individualised screening arm and judged to be at high risk will be invited to a contrast enhanced mammography and a mammography after 12 months. The intervention is thus a different selection of women compared to what is done today.
Incidence of interval cancers
For women at high 2-year risk in the intervention arm interval cancers are defined as cancers diagnosed in the interval between CEM and 12-month mammogram plus in the interval between 12- and 24-month interval. For the remaining women in the trial interval cancers are defined as cancers diagnosed between baseline mammography and 24-month mammography.
Time frame: 24-month
Number of recalled women
Information on number of women recalled from screening mammography.
Time frame: 24-month
Number of biopsies
Information on number of biopsies in recalled women.
Time frame: 24-month
Breast cancer
Y/N , if yes:date of diagonosis.
Time frame: 24-month
Tumor characteristics - Stage
Breast cancer stage 0-4
Time frame: 24-month
Tumor characteristics - Multifocality
Unifocal or multifocal
Time frame: 24-month
Tumor characteristics - Receptor status
Hormone Receptor Status, to assess the presence of estrogen receptors (ER) and progesterone receptors (PR). HER2 Status, is used to determine whether the cancer cells overexpress the HER2 protein.
Time frame: 24-month
Tumor characteristics - Proliferation
Ki-67 Index, provides information about the tumor's proliferative activity.
Time frame: 24-month
Cancer worry
Measurement of cancer worry will be done by using answers from the self-reported Cancer Worry Scale (8-item CWS). 8-item CWS measure cancer worry, score with Likert scale response, four options from min to max cancer worry.
Time frame: 24-month
Cancer anxiety
Measurement of cancer anxiety will be done by using answers from the self-reported State Trait Anxiety Inventory (STAI-6). STAI-6 measure anxiety. Questions rated on a 4-point Likert scale, options scores from "Not at all" to "Very much" anxiety.
Time frame: 24-month
Side effects related to contrast enhanced mammography
The possible side effects related to contrast enhanced mammography and ordinary mammography will be identified using the self-reported Test Morbidity Index.
Time frame: 24-month
Cost-effectiveness
Cost-effectiveness will be presented in incremental cost-effectiveness ratio (ICER).
Time frame: 24-month
Willingness-to-pay
Willingness-to-pay is defined as the maximum amount that society is willing to pay for each quality adjusted life year (QALY). One quality-adjusted life year (QALY) is equal to 1 year of life in perfect health. Scores range from 1 (perfect health) to 0 (dead).
Time frame: 24-month
No study locations are listed for this record.
Plan to share: Yes
No publications or documents are linked to this record.
Start is estimated for Apr 2024; primary completion for Apr 2028, 48 months later.
Of 328 non-industry phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 79 months of starting (the median), counting those still running; a quarter within 50 and three quarters within 127. This study's planned 48 months is below that.
Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.